LeMaitre downgraded to Neutral from Buy at Roth Capital

Roth Capital analyst David Solomon downgraded LeMaitre to Neutral from Buy, while raising the shares’ price target to $39 from $38, citing valuation after assuming coverage of the stock. The analyst notes that the company announced that it acquired Applied Medical’s vascular clot management business for $14.2M. Among the key takeaways, the analyst highlights that the acquired products bolster its line of embolectomy catheters, and points out that LeMaitre’s appetite for another acquisition remains.
https://thefly.com/landingPageNews.php?id=2798381